CDK4 and breast cancer: Given that obesity is a well-established risk factor for breast cancer, even involving the activation of molecular signalling pathways similar to those driving tumour growth, targeting CDK4/6 may provide a unified strategy to counteract both obesity-associated metabolic alterations and cancer progression.